OGT 2115

Cat. No. 2710

OGT 2115 C24H16BrFN2O4 [853929-59-6]

Price and Availability

For OGT 2115 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleacetic acid

Biological Activity

Heparanase inhibitor (IC50 = 0.4 μM) that displays no major inhibition of human cytochrome P450 isoenzymes (IC50 > 30 μM). Exhibits antiangiogenic properties in vitro (IC50 = 1 μM).

Technical Data

M.Wt:
495.3
Formula:
C24H16BrFN2O4
Solubility:
Soluble to 10 mM in DMSO
Purity:
>98 %
Storage:
Store at RT
CAS No:
853929-59-6

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

McKenzie (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br.J.Pharmacol. 151 1. PMID: 17339837.

Courtney et al (2005) Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivates: novel classes of heparanase inhibitor. Bioorg.Med.Chem.Letts. 15 2295.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses OGT 2115 from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: OGT 2115, supplier, Antiangiogenic, Heparanase, inhibitors, inhibits, Antiangiogenics, Glycosylases, Carbohydrate, Metabolism, OGT2115, Tocris Bioscience, Antiangiogenic products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.